Ublituximab + Ibrutinib in Select B-cell Malignancies
Public ClinicalTrials.gov record NCT02013128. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-center Phase II Study With Safety Run-in Evaluating the Efficacy and Safety of Ublituximab in Combination With Ibrutinib in Patients With Select B-Cell Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with Ibrutinib in patients with advanced hematologic malignancies.
Study identification
- NCT ID
- NCT02013128
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 66 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 6, 2014 (Actual)
- Primary completion
- Dec 2015 (Actual)
- Completion
- Dec 2015 (Actual)
- Last update posted
- Oct 24, 2022
2014 – 2015
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| TG Therapeutics Investigational Trial Site | Huntsville | Alabama | 35805 | — |
| TG Therapeutics Investigational Trial Site | Tucson | Arizona | 85710 | — |
| TG Therapeutics Investigational Trial Site | Santa Barbara | California | 93105 | — |
| TG Therapeutics Investigational Trial Site | Boulder | Colorado | 80303 | — |
| TG Therapeutics Investigational Trial Site | Niles | Illinois | 60714 | — |
| TG Therapeutics Investigational Trial Site | Urbana | Illinois | 61801 | — |
| TG Therapeutics Investigational Trial Site | Bethesda | Maryland | 20817 | — |
| TG Therapeutics Investigational Trial Site | Morristown | New Jersey | 07962 | — |
| TG Therapeutics Investigational Trial Site | Portland | Oregon | 97213 | — |
| TG Therapeutics Investigational Trial Site | Springfield | Oregon | 97477 | — |
| TG Therapeutics Investigational Trial Site | Greenville | South Carolina | 29615 | — |
| TG Therapeutics Investigational Trial Site | Memphis | Tennessee | 38120 | — |
| TG Therapeutics Investigational Trial Site | Austin | Texas | 78705 | — |
| TG Therapeutics Investigational Trial Site | Dallas | Texas | 75230 | — |
| TG Therapeutics Investigational Trial Site | Tyler | Texas | 75702 | — |
| TG Therapeutics Investigational Trial Site | Blacksburg | Virginia | 24060 | — |
| TG Therapeutics Investigational Trial Site | Fairfax | Virginia | 22031 | — |
| TG Therapeutics Investigational Trial Site | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02013128, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 24, 2022 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02013128 live on ClinicalTrials.gov.